MetaCap

Intercure (INCR) vs Mereo BioPharma Group (MREO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Intercure (INCR) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 50.6% versus a loss of 85.6%. Over five years, MREO leads with a -86.3% price change compared with -90.9% for INCR. Intercure is the larger company by market cap ($42.0 million vs $41.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INCR-50.57%MREO-85.56%
+34%-29%-93%
Nov 21, 20251 yearNov 20, 2026
INCR-91.77%MREO-87.06%
+152%+24%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INCR versus MREO key metrics
MetricINCRMREO
Share price$3.24$0.26
Market cap$42.03M$41.52M
1-day change-7.69%-5.45%
YTD return-28.79%-37.65%
1-year return-50.57%-85.56%
5-year return-90.87%-86.32%
EPS (TTM)$-0.95$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$500.00K
Net income (latest FY)—$-41.88M
Operating margin—-8021.40%
Net margin—-8375.60%
52-week high$7.55$2.37
52-week low$3.12$0.20
Distance from 52-week high-57.09%-89.03%
Analyst consensus—none
Avg. price target upside—+653.85%
Average volume15.93K1.24M
Shares outstanding12.97M159.70M
Employees28539
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INCR has outperformed MREO by 35.0 percentage points over the past year.

About Intercure

INCR stock →

InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.

Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees

About Mereo BioPharma Group

MREO stock →

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

INCR vs MREO FAQ

Which is bigger, Intercure or Mereo BioPharma Group?

Intercure (INCR) is larger, with a market capitalization of $42.03M compared with $41.52M for Mereo BioPharma Group (MREO).

Which stock has performed better over the past year, INCR or MREO?

INCR returned -50.57% over the past 12 months, compared with -85.56% for MREO (price return, excluding dividends). Past performance does not predict future results.

Are Intercure and Mereo BioPharma Group in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons